Depotstart eines Fast-Newbies (Seite 170)
eröffnet am 17.04.20 04:06:15 von
neuester Beitrag 07.05.24 00:19:10 von
neuester Beitrag 07.05.24 00:19:10 von
Beiträge: 2.901
ID: 1.323.442
ID: 1.323.442
Aufrufe heute: 14
Gesamt: 208.738
Gesamt: 208.738
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 45 Minuten | 7532 | |
| vor 23 Minuten | 7199 | |
| vor 45 Minuten | 4575 | |
| vor 1 Stunde | 3991 | |
| 02.02.07, 20:48 | 2684 | |
| vor 29 Minuten | 2457 | |
| vor 43 Minuten | 1876 | |
| vor 24 Minuten | 1706 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.713,28 | +1,10 | 198 | |||
| 2. | 7. | 0,3100 | -67,71 | 106 | |||
| 3. | 4. | 0,2100 | +8,53 | 83 | |||
| 4. | 2. | 160,16 | -1,44 | 48 | |||
| 5. | 38. | 2,5655 | +9,61 | 46 | |||
| 6. | 9. | 6,6420 | -0,09 | 35 | |||
| 7. | 12. | 0,1661 | -4,98 | 34 | |||
| 8. | 5. | 4,1500 | -0,60 | 34 |
Beitrag zu dieser Diskussion schreiben
Feedback
hier nochmal PAVM - die Langzeiteinordnung! Tapfere Jungs.
http://www.pavmed.com/
http://www.pavmed.com/business-model/
http://www.pavmed.com/
http://www.pavmed.com/business-model/
@ PLTR - nachbörslich 7 % vorne. Ehrlich gesagt fand ich den Abverkauf heute komplett unangebracht. So what! 
🙃
die 2025 Ansage hat die Analysten im call ganz schön weggeblasen, bin auf die updates gespannt.
PLTR wird einmal sehr schöne Margen bekommen. Füße stillhalten. Schwäche kaufen.
🙃die 2025 Ansage hat die Analysten im call ganz schön weggeblasen, bin auf die updates gespannt.
PLTR wird einmal sehr schöne Margen bekommen. Füße stillhalten. Schwäche kaufen.
Neuvorstellung PAVM - Pavmed. Contest-teilnehmer von patriots!
Karpal-Tunnel-Syndrom kennen wahrscheinlich die meisten. Verdammt unangenehm und langwierig in der Behandlung.
https://www.marketscreener.com/quote/stock/PAVMED-INC-303531…
https://finance.yahoo.com/news/first-u-patient-undergoes-suc…
"The patient presented with symptoms of carpal tunnel syndrome to Dr. Edward J. Armbruster of Mercer-Bucks Orthopaedics, P.C., in greater Philadelphia, who performed minimally invasive carpal tunnel release using the CarpX device. In marked contrast to typical recovery times of up to several months following conventional carpal tunnel release surgery, the patient returned to work as a truck driver within one week of the procedure.
“This is a very exciting development and the most significant advance in minimally invasive carpal tunnel release since endoscopic techniques were introduced some 30 years ago” said Dr. Armbruster. “I found that the CarpX balloon creates significantly more space in the carpal tunnel after the transverse carpal ligament is divided than traditional techniques, which could potentially result in superior outcomes for patients. As a busy hand surgeon, I strongly believe that CarpX will change how future carpal tunnel surgery will be performed, providing patients with a less invasive option with significantly shorter recovery times than existing carpal tunnel release options.” "
und nicht nur das kann PAVN:
>>> https://seekingalpha.com/article/4404684-pavmeds-esophageal-…
"EsoCheck is not designed to be a replacement for all situations in which an EGD would be needed (for example, an EGD will still be needed if adverse findings are obtained from an EsoCheck screening), but EsoCheck is a far easier, more pleasant, and more convenient method to screen for Barrett’s in high-risk patients. EsoCheck requires no sedation and is a simple, five-minute outpatient procedure."
>>> vereinfachtes screening zu Speiseröhrenkrebs.
PAVmed recently announced that it received a final determination from CMS that Medicare will be covering EsoGuard at a price of $1,938.01 starting on January 1, 2021. This will hopefully set the tone for the company in getting private payors to follow suit, and it finally allows the company to begin meaningfully trying to ramp-up sales in 2021.
https://de.wikipedia.org/wiki/Speiser%C3%B6hrenkrebs
"Certain cancers already have well-adopted screening measures in place. Notable examples that come to mind are colorectal cancer with colonoscopies and now Cologuard, breast cancer with mammograms, and cervical cancer with the pap test. Esophageal cancer is not one of those with meaningful screening though, yet it represents one of the fastest growing and most deadly cancer threats around."
Fazit: PAVM hat da jede Menge am Start und ist noch günstig zu haben. Wen wundert es - Aktie in den letzten Tagen angesprungen:
+++
sorry - einmal mehr medtech - gibt aber schlimmeres.
🕯
lg cleara
Karpal-Tunnel-Syndrom kennen wahrscheinlich die meisten. Verdammt unangenehm und langwierig in der Behandlung.
https://www.marketscreener.com/quote/stock/PAVMED-INC-303531…
https://finance.yahoo.com/news/first-u-patient-undergoes-suc…
"The patient presented with symptoms of carpal tunnel syndrome to Dr. Edward J. Armbruster of Mercer-Bucks Orthopaedics, P.C., in greater Philadelphia, who performed minimally invasive carpal tunnel release using the CarpX device. In marked contrast to typical recovery times of up to several months following conventional carpal tunnel release surgery, the patient returned to work as a truck driver within one week of the procedure.
“This is a very exciting development and the most significant advance in minimally invasive carpal tunnel release since endoscopic techniques were introduced some 30 years ago” said Dr. Armbruster. “I found that the CarpX balloon creates significantly more space in the carpal tunnel after the transverse carpal ligament is divided than traditional techniques, which could potentially result in superior outcomes for patients. As a busy hand surgeon, I strongly believe that CarpX will change how future carpal tunnel surgery will be performed, providing patients with a less invasive option with significantly shorter recovery times than existing carpal tunnel release options.” "
und nicht nur das kann PAVN:
>>> https://seekingalpha.com/article/4404684-pavmeds-esophageal-…
"EsoCheck is not designed to be a replacement for all situations in which an EGD would be needed (for example, an EGD will still be needed if adverse findings are obtained from an EsoCheck screening), but EsoCheck is a far easier, more pleasant, and more convenient method to screen for Barrett’s in high-risk patients. EsoCheck requires no sedation and is a simple, five-minute outpatient procedure."
>>> vereinfachtes screening zu Speiseröhrenkrebs.
PAVmed recently announced that it received a final determination from CMS that Medicare will be covering EsoGuard at a price of $1,938.01 starting on January 1, 2021. This will hopefully set the tone for the company in getting private payors to follow suit, and it finally allows the company to begin meaningfully trying to ramp-up sales in 2021.
https://de.wikipedia.org/wiki/Speiser%C3%B6hrenkrebs
"Certain cancers already have well-adopted screening measures in place. Notable examples that come to mind are colorectal cancer with colonoscopies and now Cologuard, breast cancer with mammograms, and cervical cancer with the pap test. Esophageal cancer is not one of those with meaningful screening though, yet it represents one of the fastest growing and most deadly cancer threats around."
Fazit: PAVM hat da jede Menge am Start und ist noch günstig zu haben. Wen wundert es - Aktie in den letzten Tagen angesprungen:
+++
sorry - einmal mehr medtech - gibt aber schlimmeres.
🕯lg cleara
@ BCRX - Ende der Konsolidierung:
+++
Upcoming Quarter’s Earnings
Announce date
2/25/2021
+++
Upcoming Quarter’s Earnings
Announce date
2/25/2021
EHang - die Drohne ist gelandet. China at it's best.
short report von wolfpack.
https://seekingalpha.com/news/3662427-ehang-falls-after-new-…
https://wolfpackresearch.com/research/ehang/
-65%, nachbörslich + 25 %
"• Kunxiang has an exaggerated physical presence and its real operations appear to be a fraction of what is claimed. Out of the 3 addresses listed on Kunxiang’s website, one is a hotel with no Kunxiang presence, one is a 13th floor address of an 11-story building, and the last one had only one Kunxiang employee in the office on a weekday afternoon.
• To the extent Kunxiang actually does sell vehicles, it did not want to sell EH’s products to us. When asked, the only employee on-site at Kunxiang, who claimed to be the finance manager, had no hesitation voicing his disapproval of the EH216, and instead offered their own, supposedly much higher quality products for sale."
short report von wolfpack.
https://seekingalpha.com/news/3662427-ehang-falls-after-new-…
https://wolfpackresearch.com/research/ehang/
-65%, nachbörslich + 25 %
"• Kunxiang has an exaggerated physical presence and its real operations appear to be a fraction of what is claimed. Out of the 3 addresses listed on Kunxiang’s website, one is a hotel with no Kunxiang presence, one is a 13th floor address of an 11-story building, and the last one had only one Kunxiang employee in the office on a weekday afternoon.
• To the extent Kunxiang actually does sell vehicles, it did not want to sell EH’s products to us. When asked, the only employee on-site at Kunxiang, who claimed to be the finance manager, had no hesitation voicing his disapproval of the EH216, and instead offered their own, supposedly much higher quality products for sale."
Trading Spotlight
@ PLTR - c-call
https://seekingalpha.com/article/4406413-palantir-technologi…
"For our five-year outlook, we expect greater than $4 billion in revenue in 2025. Starting in 2021, we expect greater than 30% annual revenue growth each year for the next five years. And in Q1 of this year, we expect revenue growth of 45% or $332 million at the midpoint and we expect adjusted operating margin of 23% for the quarter."
Alex Karp - kein Mann der kleinen Worte:
"And to do that, we’re providing long-term guidance pretty radical in the sense that we are committing to keeping a growth threshold of above 30% for the next five years, but not focused on the day-to-day, quarter-to-quarter near-term focus that quite frankly destroys businesses is one of the main reasons why so many of our businesses, especially in tech are actually only serving Wall Street and not serving their clients and not serving an everyday investor and generate suboptimal returns over time, because they too are lacking indicator of the suboptimal performance."
Shyam Sankar
"I’ll build on what Karp said earlier in the call on long-term guidance. We are very much at the beginning here. We just did 45% growth in 2020. We expect to do – sorry, 47% growth in 2020. We expect to do 45% growth in Q1 of 2021 and we are only in 24 of the global 300. But I think looking at that kind of misses the point around the TAM expansion, that’s currently happening. Look at the channel partnership with Fujitsu and IBM among others, where we’re not just distributing to the top 300 or the top 1,000, but really, we have the ability now to distribute to the entire market, potentially tens of thousands of customers."
https://seekingalpha.com/article/4406413-palantir-technologi…
"For our five-year outlook, we expect greater than $4 billion in revenue in 2025. Starting in 2021, we expect greater than 30% annual revenue growth each year for the next five years. And in Q1 of this year, we expect revenue growth of 45% or $332 million at the midpoint and we expect adjusted operating margin of 23% for the quarter."
Alex Karp - kein Mann der kleinen Worte:
"And to do that, we’re providing long-term guidance pretty radical in the sense that we are committing to keeping a growth threshold of above 30% for the next five years, but not focused on the day-to-day, quarter-to-quarter near-term focus that quite frankly destroys businesses is one of the main reasons why so many of our businesses, especially in tech are actually only serving Wall Street and not serving their clients and not serving an everyday investor and generate suboptimal returns over time, because they too are lacking indicator of the suboptimal performance."
Shyam Sankar
"I’ll build on what Karp said earlier in the call on long-term guidance. We are very much at the beginning here. We just did 45% growth in 2020. We expect to do – sorry, 47% growth in 2020. We expect to do 45% growth in Q1 of 2021 and we are only in 24 of the global 300. But I think looking at that kind of misses the point around the TAM expansion, that’s currently happening. Look at the channel partnership with Fujitsu and IBM among others, where we’re not just distributing to the top 300 or the top 1,000, but really, we have the ability now to distribute to the entire market, potentially tens of thousands of customers."
Antwort auf Beitrag Nr.: 67.011.483 von clearasil am 15.02.21 11:17:24
FacebookTwitterLinkedInShare Licensing
REINHARDT KRAUSE07:32 AM ET 02/16/2021
Palantir Technologies (PLTR) on Tuesday reported December quarter earnings and revenue that topped estimates as it closed several large deals. Palantir stock fell in early trading as full-year 2021 revenue guidance came in slightly below expectations.
Heading into the Palantir earnings report, the enterprise software stock traded just below a buy zone.
For the fourth quarter, Palantir reported a loss of 8 cents per share, including stock-based ...
https://finance.yahoo.com/m/481f8dc0-1812-329c-8263-28fde01b…
Aktuell – 10%
Mk ist ja immer noch 55 Mrd US$
Palantir werden heute etwas abgestraft …
Palantir Stock Falls As 2021 Revenue Growth Outlook Below ExpectationsFacebookTwitterLinkedInShare Licensing
REINHARDT KRAUSE07:32 AM ET 02/16/2021
Palantir Technologies (PLTR) on Tuesday reported December quarter earnings and revenue that topped estimates as it closed several large deals. Palantir stock fell in early trading as full-year 2021 revenue guidance came in slightly below expectations.
Heading into the Palantir earnings report, the enterprise software stock traded just below a buy zone.
For the fourth quarter, Palantir reported a loss of 8 cents per share, including stock-based ...
https://finance.yahoo.com/m/481f8dc0-1812-329c-8263-28fde01b…
Aktuell – 10%
Mk ist ja immer noch 55 Mrd US$
@KLR
https://finance.yahoo.com/news/kaleyra-announces-highest-qua…
Kaleyra Announces Highest Quarterly Revenue for Fourth Quarter and Full Year 2020 Financial Results Exceeding Revenue Guidance
Tue, February 16, 2021, 1:00 PM
Total fourth quarter revenue of $44.3 million, a 16% increase from Q3 and up 24% from the same period a year ago
Revenue from US Customers was $6.9 million, up over 100% from the same period a year ago
Delivered 7.1 billion billable messages and connected 1.4 billion voice calls
Kaleyra, Inc. (NYSE: KLR) (KLR WS) ("Kaleyra" or the "Company") a rapidly growing cloud communications software provider delivering a secure system of application programming interfaces (APIs) and connectivity solutions in the API/Communications Platform as a Service (CPaaS) market, today announced financial results for the fourth quarter and full year ended December 31, 2020.
"We once again have exceeded our revenue guidance and delivered our strongest quarter ever. The fourth quarter was an excellent finish to a challenging year, and our continued success in this environment serves to validate the strength of our model and strategy. As enterprise customers are increasingly looking for new ways to engage with their customers, our platform and strong value proposition have made Kaleyra a mission critical addition to their customer outreach," commented Dario Calogero, Kaleyra’s Founder and Chief Executive Officer. "We are thrilled to begin 2021 with a high level of momentum provided by strong execution from our entire team, our robust platform of flexible APIs, and our unwavering commitment to helping our customers succeed."
Fourth Quarter 2020 Financial Highlights
Revenue: Total revenue for the fourth quarter of 2020 was $44.3 million, a 16% increase when compared to Q3 revenue of $38.3 million and up 24% compared to $35.6 million in the fourth quarter of 2019.
Gross Profit: Gross profit for the fourth quarter of 2020 was $7.8 million, a 5% increase when compared to Q3 gross profit of $7.5 million and down 3% compared to $8.1 million for the fourth quarter of 2019. Gross margin for the fourth quarter of 2020 was 18%. Declining volumes in the first half of the year caused by COVID created a negative residual effect on margins in the fourth quarter.
Net Loss: Net loss for the fourth quarter of 2020 was $(4.5) million, or $(0.15) per share, based on 29.7 million weighted-average shares outstanding. During the fourth quarter of 2019, net loss was $(3.6) million, or $(0.25) per share, based on 14.3 million weighted-average shares outstanding.
+++
@PLTR - Umsatz mit 20 mio besser als erwatet. eps niedriger als erartet wg. Ausgaben für Marketing und Wachstum.
Woche wird allemal wild, da auch noch lock-up-ende ist.
Ich halte die Füße still.
https://finance.yahoo.com/news/kaleyra-announces-highest-qua…
Kaleyra Announces Highest Quarterly Revenue for Fourth Quarter and Full Year 2020 Financial Results Exceeding Revenue Guidance
Tue, February 16, 2021, 1:00 PM
Total fourth quarter revenue of $44.3 million, a 16% increase from Q3 and up 24% from the same period a year ago
Revenue from US Customers was $6.9 million, up over 100% from the same period a year ago
Delivered 7.1 billion billable messages and connected 1.4 billion voice calls
Kaleyra, Inc. (NYSE: KLR) (KLR WS) ("Kaleyra" or the "Company") a rapidly growing cloud communications software provider delivering a secure system of application programming interfaces (APIs) and connectivity solutions in the API/Communications Platform as a Service (CPaaS) market, today announced financial results for the fourth quarter and full year ended December 31, 2020.
"We once again have exceeded our revenue guidance and delivered our strongest quarter ever. The fourth quarter was an excellent finish to a challenging year, and our continued success in this environment serves to validate the strength of our model and strategy. As enterprise customers are increasingly looking for new ways to engage with their customers, our platform and strong value proposition have made Kaleyra a mission critical addition to their customer outreach," commented Dario Calogero, Kaleyra’s Founder and Chief Executive Officer. "We are thrilled to begin 2021 with a high level of momentum provided by strong execution from our entire team, our robust platform of flexible APIs, and our unwavering commitment to helping our customers succeed."
Fourth Quarter 2020 Financial Highlights
Revenue: Total revenue for the fourth quarter of 2020 was $44.3 million, a 16% increase when compared to Q3 revenue of $38.3 million and up 24% compared to $35.6 million in the fourth quarter of 2019.
Gross Profit: Gross profit for the fourth quarter of 2020 was $7.8 million, a 5% increase when compared to Q3 gross profit of $7.5 million and down 3% compared to $8.1 million for the fourth quarter of 2019. Gross margin for the fourth quarter of 2020 was 18%. Declining volumes in the first half of the year caused by COVID created a negative residual effect on margins in the fourth quarter.
Net Loss: Net loss for the fourth quarter of 2020 was $(4.5) million, or $(0.15) per share, based on 29.7 million weighted-average shares outstanding. During the fourth quarter of 2019, net loss was $(3.6) million, or $(0.25) per share, based on 14.3 million weighted-average shares outstanding.
+++
@PLTR - Umsatz mit 20 mio besser als erwatet. eps niedriger als erartet wg. Ausgaben für Marketing und Wachstum.
Woche wird allemal wild, da auch noch lock-up-ende ist.
Ich halte die Füße still.
Antwort auf Beitrag Nr.: 67.011.483 von clearasil am 15.02.21 11:17:24
Kommen böse unter die Räder momentan
Zitat von clearasil: bis sehr gespannt auf PLTR-Ergebnisse morgen.
Kommen böse unter die Räder momentan
Antwort auf Beitrag Nr.: 67.031.622 von Murmeltier81 am 16.02.21 12:52:06https://seekingalpha.com/news/3662001-nano-dimension-prices-…
Aus den Kommentaren entnehme ich, das sie nun bereits 11 Offerings in 12 Monaten hatten? Was sind denn deine Trigger für Nano Dimension? Bei 3D werde ich hellhörig, möchte in dem Sektor eigentlich auch investiert sein
Aus den Kommentaren entnehme ich, das sie nun bereits 11 Offerings in 12 Monaten hatten? Was sind denn deine Trigger für Nano Dimension? Bei 3D werde ich hellhörig, möchte in dem Sektor eigentlich auch investiert sein
Durchsuchen
